CHAMPION-AF Clinical Trial (CHAMPION-AF)

• ClinicalTrials.gov Identifier: NCT04394546
• Recruitment Status: Active, not recruiting
• First Posted: May 19, 2020
• Last Update Posted: April 23, 2024
• Sponsor: Boston Scientific Corporation
• Information provided by (Responsible Party): Boston Scientific Corporation

Tracking Information

• First Submitted Date: May 14, 2020
• First Posted Date: May 19, 2020
• Last Update Posted Date: April 23, 2024
• Actual Study Start Date: October 15, 2020
• Estimated Primary Completion Date: December 2027 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 11, 2021)

• WATCHMAN FLX is non-inferior (NI) for the occurrence of stroke, cardiovascular death, and systemic embolism [ Time Frame: 36-months ]
  non-inferiority
• WATCHMAN FLX is superior for non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding) [ Time Frame: 36-months ]
  superiority
• WATCHMAN FLX is non-inferior (NI) for the occurrence of ischemic stroke and systemic embolism [ Time Frame: 60-months ]
  non-inferiority

• Original Primary Outcome Measures: Not Provided

Current Secondary Outcome Measures (submitted: March 22, 2022)

• The occurrence of ISTH major bleeding [ Time Frame: 60-months ]
  superiority
• The occurrence of cardiovascular (CV) death, all stroke, systemic embolism (SE), and non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding) [ Time Frame: 60-months ]
  superiority

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: CHAMPION-AF Clinical Trial
• Official Title: WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
• Brief Summary: The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
• Detailed Description: This study is a prospective, randomized, multi-center global investigation. Subjects will be randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device ("Device Group") or a commercially available non-vitamin K oral anticoagulant ("Control Group").
• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Single (Outcomes Assessor); Primary Purpose: Prevention

Condition

• Atrial Fibrillation
• Stroke
• Bleeding

Intervention

• Device: WATCHMAN FLX LAAC Device
  WATCHMAN FLX LAAC Device Implantation
  Other Name: WATCHMAN FLX Left Atrial Appendage Closure Device
• Drug: Non-Vitamin K Oral Anticoagulant
  Initiation or continuation of a NOAC drug
  Other Name: NOAC

Study Arms

• Experimental: Device Group
  Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
  Intervention: Device: WATCHMAN FLX LAAC Device
• Active Comparator: Control Group
  Randomized to non-vitamin K oral anticoagulant (NOAC)
  Intervention: Drug: Non-Vitamin K Oral Anticoagulant

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: November 4, 2020): 3000
• Original Enrollment: Not Provided
• Estimated Study Completion Date: December 2027
• Estimated Primary Completion Date: December 2027 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• The subject is of legal age to participate in the study per the laws of their respective geography
• The subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve)
• The subject has a calculated CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category) score of 2 or greater for men and 3 or greater for women
• The subject is deemed to be suitable for the protocol-defined pharmacologic regimens in both the test and control arms
• The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial
• The subject is able and willing to return for required follow-up visits and examinations

Exclusion Criteria:

• Subjects who are currently enrolled in another investigational study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments
• The subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction, for example due to an underlying hypercoagulable state (i.e., even if the device is implanted, the subjects would not be eligible to discontinue OAC due to other medical conditions requiring chronic OAC therapy)
• The subject is contraindicated or allergic to oral anticoagulation medication and/or aspirin
• The subject is indicated for chronic P2Y12 platelet inhibitor therapy
• The subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to: cardioversion, percutaneous coronary intervention (PCI), cardiac ablation, cataract surgery, etc.)
• The subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment
• The subject had a prior major bleeding event per ISTH definition within the 30 days prior to randomization. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event
• The subject has an active bleed
• The subject has a reversible cause of AF or transient AF
• The subject is absent of a left atrial appendage (LAA) or the LAA is surgically ligated
• The subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment
• The subject has a history of atrial septal repair or has an atrial septal device (ASD)/patent foramen ovale (PFO) device
• The subject has an implanted mechanical valve prosthesis in any position
• The subject has a known contraindication to percutaneous catheterization procedure
• The subject has a known contraindication to transesophageal echo (TEE)
• The subject has a cardiac tumor
• The subject has signs/symptoms of acute or chronic pericarditis.
• The subject has an active infection
• There is evidence of tamponade physiology
• The subject has New York Heart Association Class IV Congestive Heart Failure at the time of enrollment
• The subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment upon study physician's discretion)
• The subject has a documented life expectancy of less than 3 years

Transthoracic Echo Exclusion Criteria:

• The subject has left ventricular ejection fraction ( LVEF) < 30%
• The subject has an existing pericardial effusion with a circumferential echo-free space > 5mm
• The subject has a high-risk PFO with an atrial septal aneurysm excursion > 15mm or length > 15mm
• The subject has significant mitral valve (MV) stenosis (i.e., MV area <1.5 cm2)

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Saudi Arabia, Spain, Switzerland, United Kingdom, United States

Administrative Information

• NCT Number: NCT04394546
• Other Study ID Numbers: S2437
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes

IPD Sharing Statement

• Plan to Share IPD: Yes
• Supporting Materials: Study Protocol
• URL: http://www.bostonscientific.com/content/gwc/en-US/data-sharing-requests.html

• Current Responsible Party: Boston Scientific Corporation
• Original Responsible Party: [Redacted]
• Current Study Sponsor: Boston Scientific Corporation
• Original Study Sponsor: [Redacted]
• Collaborators: Not Provided

Investigators

• Study Chair: Marty Leon, MD; New York-Presbyterian Heart Valve Center/Columbia University Irving Medical Center
• Study Chair: Kenneth A Ellenbogen, MD; Virginia Commonwealth University
• Principal Investigator: Shephal Doshi, MD; Pacific Heart Institute and Providence St. John's Health Center
• Principal Investigator: Saibal Kar, MD; HCA Healthhcare /Los Robles Health System

• PRS Account: Boston Scientific Corporation
• Verification Date: March 2024